AstraZeneca stock dives 9% after heart drug trial misses target

AstraZeneca's stock plummeted 9% after its latest heart drug trial fell short of its primary goal, signaling a setback in the company's efforts to bolster its cardiovascular portfolio. The trial's failure highlights the challenges drugmakers face in developing effective treatments for heart conditions, which are among the leading causes of death worldwide. This outcome not only impacts investor confidence but also underscores the urgency for the pharmaceutical industry to find reliable solutions for heart disease, a global health concern.